Effect of Growth Hormone therapy in Liver failure patients
Phase 2
- Conditions
- Health Condition 1: K703- Alcoholic cirrhosis of liver
- Registration Number
- CTRI/2022/12/048572
- Lead Sponsor
- ICMR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Alcoholic hepatitis associated ACLF patients
2. Age 18-80 years
3. Availability of informed consent
Exclusion Criteria
1. Hepatocellular carcinoma or active malignancy
2. Prior treatment with glucocorticoids and experimental therapies
3. Acute kidney injury, multi-organ failures ( >two)
4. Uncontrolled UGI-bleed <48 hours
5. HIV infection and other confounding etiologies (HAV, HEV, HBV, HCV, Autoimmune hepatitis, Wilson disease, Hemochromatosis)
6. Pregnancy and lactation
7. CLIF-C ACLF score >60, AARC score >11, MELD = 30
8. Uncontrolled infection or sepsis
9. Known hypersensitivity to GH or it’s adjuvants
10. Uncontrolled diabetes (Hb A1c = 9) or diabetic retinopathy.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method